The combined companies will have a broad commercial-stage diagnostics portfolio of CE-IVD-marked and US-FDA cleared products and platforms, as well as a proprietary NGS-based and AI-powered technology and knowledgebase for the rapid molecular prediction of AMR. The initial two main focuses for the company will be
(a) rapid diagnostics for lower respiratory infection and urinary tract infection and
(b) bioinformatics and NGS services for AMR prediction by Ares Genetics as well as bioinformatics services based on the Acuitas Lighthouse® AMR knowledgebase by OpGen.
Read Full Details at ir.opgen.com
Note: This content has been edited by a rapidmicrobiology staff writer for style and content.
